Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Liabilities (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Total Liabilities for 14 consecutive years, with $241.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 9.47% year-over-year to $241.5 million, compared with a TTM value of $241.5 million through Dec 2025, down 9.47%, and an annual FY2025 reading of $241.5 million, down 9.47% over the prior year.
  • Total Liabilities was $241.5 million for Q4 2025 at Heron Therapeutics, up from $234.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $266.8 million in Q4 2024 and bottomed at $114.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $242.2 million, with a median of $249.6 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 124.67% in 2021, then decreased 10.24% in 2025.
  • Year by year, Total Liabilities stood at $228.1 million in 2021, then rose by 4.05% to $237.4 million in 2022, then grew by 8.05% to $256.5 million in 2023, then grew by 4.02% to $266.8 million in 2024, then dropped by 9.47% to $241.5 million in 2025.
  • Business Quant data shows Total Liabilities for HRTX at $241.5 million in Q4 2025, $234.1 million in Q3 2025, and $259.3 million in Q2 2025.